Trial Profile
TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms TECOS
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 29 Oct 2021 Results assessing cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease from TECOS) study, published in the Diabetes Care.
- 04 Jul 2020 Results assessing secondary analysis of TECOS participants with time to event analyses using multivariable Cox proportional hazard models published in the European Journal of Heart Failure
- 13 Nov 2019 Results of Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease has published in the American Heart Journal